1. You are what you exhale Every time that we exhale We release volatile compounds

2. Scientists can analyze our breath They collect all the volatiles …and tell you how healthy are your lungs!

3. Now imagine what we can do… lung information piece of exhaled air

4. The answer is… We are a company that develops medical devices to analyze breath and diagnose “Tuberculosis” and “Aspergillosis” at same TIME!

5. Why Tuberculosis and Aspergillosis? Tuberculosis and Aspergillosis share the same clinical presentation. The bronchoalveolar lavage to diagnose aspergillosis is invasive and painful.

6. Why Tuberculosis and Aspergillosis? 7,982 cases of Tuberculosis were notified in the UK in 2013 Aspergillosis affects over 1,000,000 people Over 25,000 deaths are estimated every year 95 % of Tuberculosis occurred in developing countries Over 3,000,000 cases of Aspergillosis were reported worldwide. 12 % of those cases were related to tuberculosis. Over 3,000,000 cases of Aspergillosis were reported worldwide. 12 % of those cases were related to tuberculosis.

7. Breath analysis: from invasive to non-invasive PCR methods & Antobodies tests Mass spectrometry & Gas chromatography Breath analysis with gold & carbon nanoparticles Gold & carbon nanoparticles specific to volatile chemicas from Aspergillus and Tuberculosis

8. How to transport the air to the breath analyzer? Mask Platform: Voltron 1.0

9. Competitive advantage Turn-around time at least 12 hours Invasive 64.5% sensitivity 93.2% specificity Price range £75-£1,500 Detection in 1 min Non-invasive 96.7 % sensitivity 98.3 % specificity Portable Price £40 OUPS!

10. Market Segmentation Respiratory Diagnosis Global Market by revenue Market stage: increasing 1.6 B by 2017 and revenue growth rate is 5.7%. Competitive factors: life span, reliability, availability, product cost, and service quality. Biosensors Global Market share by revenue United States Japan Germany Others South Africa China UK Brazil India Mexico Small companies F. Hoffman-La Roche LTd. Siemens Medical Abbott Beckman BioMerieux Beckton Dickinson Bio-Rad inc Number of companies in the Market: 25 Top 3 companies control 45.4% of market share

11. Company Story In 2014 we started to collect literature information about volatile biomarkers for Voltron 1. First prototype of mask Validation with clinical trials at the National Center of Aspergillus in Southern Manchester, notified to the MHRA (Medicines and Healthcare products Regulatory Agency), fee £5,040 Conformity assessment for CE marking carried out by BSI Healthcare, fee £8,000 Licensing to Omega Diagnostic Ltd (Manufacture) Licensing to Avenzys Medical (Distributor)

12. Distribution Channels & Advertising Medical advocates End user Direct Sales 26.7% Distributors 63.5% Online sales 9.8% Special promotions Advertising & Publicity Hospitals, Point Care Centres, Respiratory Clinics, Nursing Homes Governments, Airports, Immigration, Infection Control & Surveillance

13. Operations Year 1 Sale of licenses of Voltron 1.0 The product is designed in the UK, licensed to Omega Diagnostic Ltd for manufacture. The product is licensed for distribution to Avenzys Medical Main income comes from licences sale: 100%. Direct channels of communications with potential customers are medical exhibitions and face-to-face marketing. Development of breath analysers Diabetes (Voltron 2) Cancer (Voltron 3) Arthritis (Voltron 4)

14. Operations Year 3 Distribution and Sales of Voltron 1 Main selling is done by us: Direct channels are medical exhibitions and face-to- face marketing. Main income: 60% sales, 40% licenses. Manufacture of Voltron 1 Voltron 1 was designed in the UK: manufacture is licensed to Omega Diagnostic Ltd in the UK. Post-manufacturing surveillance via technical support line by Omega Diagnostic Ltd. Sale of Licenses: manufacture and distribution Breath analyzers to diagnose Diabetes (Voltron 2) Breath analyzers to diagnose cancer (Voltron 3).

15. Operations Year 6 Distribution of Voltron 1 Voltron 1 was designed in the UK: manufacture and distribution are controlled by us Distribution in the UK: Phone representative and online platform. Distribution in Latin American and African countries via representatives and licenses. Distribution in main airports in UK and Germany. Main selling is done by us: Direct channels are medical exhibitions and face-to- face marketing. Income: 60% sales, 40% licenses Manufacture of Voltron 1 Manufacture is controlled by Volatronics. (Register as manufacturer in Year 5) Post-manufacturing surveillance via technical support line in the UK. Sales of licenses: manufacture and distribution Breath analyzer for Diabetes (Voltron 2) Breath analyzer for Cancer (Voltron 3) Breath analyzer for Arthritis (Voltron 4).

16. Human resources Aaron Hernandez Cid (CEO): Aaron is a true entrepreneur, and a co-founder of several start-ups (e.g. Cloudpaper), Starting in "Los Zetas Corp." Juarez, Mexico where he had the role of CEO and continuing to head Beltrán-Leyva Ltd. dealing mostly with oil. Aaron found out from the news about the severe breathing problems his corporation had caused, in fact after suffering from a personal family loss he've decided to start up a company which will provide cheap solutions for any breath detectable illnesses, he teamed up with Evaldez a young researcher and decided to start with fungus detection in lungs. Evaldez Klumbys (R & D): Young researcher, after finishing his PhD in Fungus research and lung deseases etc. he started to look for practical opportunities to make some money. He gained some work experience in the GSK where he has developed a special mask design for breath analysis. He travelled to several conferences where he met Aaaron during one of the Pitch for investment sessions. Evaldez was glad to take the role of R&D director in Volatronics. Aiah Khateb. (Marketing): M.Sc in Microbiology and Infectious Diseases at Calgary's Center of Antimicrobial Resistance, Canada. Winner of Canadian Microbiology Marketing Award, 2014, Victoria AMMI Canada. Has 2 years marketing experience from the Canadian innovation centre. Currently works on identifying novel Molecular Detection & Mechanisms of Antifungal Resistance in Aspergillus fumigatus as a researcher, at University of Manchester. Always felt like there is not enough exposure to the dangers and severity of illnesses related to fungus. As a leading researcher in this field Aiah felt obligated to join any company that will address fungus related illnesses and especially she was happy to take the marketing role as she is very passionate and motivated to rise awareness in this field.

17. Human resources Tania Sanchez Monroy. (Financials): Spending several years in TWAS (The Third World Academy of Sciences) grants committee as a judge and for another 2 years as an advisor in a Governmental “Business and Science” committee of Mexico. Tania has all the skills and networking needed to get the funds and investments and to keep the company profitable Specialities: Strategic Planning, Technology & Innovation Management, Materials science and biomechanics,, Team working, Health industry partnership projects. Leonid Nichman. (HR & Operations): M.Sc Chemistry and Materials science, had 5 years of experience of operations and logistics in a printing corporation. dealing with suppliers, processing orders and building the whole logistics chain. Leonid won the VentureOut prize of 2015 for his ideas for improvements of Graphene production lines. Leonid is a team player and an HR specialist with a long experience of managing and coordinating international and multidisciplinary teams at CERN. Leonid is a polyglot with a deep knowledge of Mandarin which facilitates the collaboration with our manufacturers in China.

18. Strengths, Weakness, Opportunity & Threats Strengths: Key player in rapid detection kits market Unique and novel detection technique Backed by scientific authorities of the field Focus on product R&D in broadening horizontal applications Weakness Weak brand reputation Local activity on national scale Early stage, high risk for investors Opportunities Solutions for different invasive diseases. Upgrading the current immobile analysis stations in hospitals and clinics to portable devices Become a self-distributor Large investment in R&D and patenting Customer’s health leads to growth in reputation and increase of clients Threats Medium accuracy of detection There is no unified database with breath data, which limits R&D Competitive threat from companies with similar emerging technology

19. Financials & Profitability Sales forecast This and the other financials statements are based on best guesses. Relevant info: market analysis indicates that 62% of profit for the biosensor market is generated by distributors, 12% by manufacturers. We license the technology to manufacture and distribute, but we are concerned to develop new products to diagnose lung cancer, diabetes and arthritis. UK is a leading country in research for developing new medical devices, grants of research councils and also the market of infectious diseases is 80% based on LATAM, therefore cheap devices and easy to use are relevant.

20. Financials & Profitability Profit and loss account Cash flow forecast Everything is based on best guesses.

21. Roadmap